Nolibeta (Nebivolol)

Nebivolol is used to manage cardiovascular conditions that involve elevated blood pressure or impaired cardiac function.

• Hypertension: lowers systemic blood pressure and reduces cardiovascular risk.
• Chronic heart failure: improves left‑ventricular ejection fraction and decreases hospitalization rates.
• Post‑myocardial infarction (when indicated): helps prevent subsequent cardiac events.

• Nebivolol selectively blocks β1‑adrenergic receptors, reducing heart rate and myocardial contractility. In addition, it stimulates endothelial nitric oxide synthase, leading to nitric‑oxide mediated vasodilation, which further contributes to blood pressure reduction.

Nebivolol may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Headache: mild to moderate intensity.
• Dizziness or light‑headedness: especially on standing.
• Fatigue: general tiredness.
• Nasal congestion: mild blockage of nasal passages.
• Bradycardia: slower than normal heart rate.
• Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects

• Severe bradycardia: heart rate dropping below 40 bpm.
• Heart block: atrioventricular conduction disturbances.
• Acute heart failure exacerbation.
• Angioedema: swelling of face, lips, or throat.
• Hypotension: marked drop in blood pressure causing faintness.
• Liver enzyme elevation: abnormal hepatic function tests.

Before prescribing Nolibeta, clinicians should consider several safety aspects.

• Cardiovascular assessment: evaluate for severe bradycardia or heart block.
• Renal function: adjust use in patients with significant renal impairment.
• Hepatic impairment: use cautiously in moderate to severe liver disease.
• Concomitant beta‑blockers: avoid additive effects that may cause excessive slowing of heart rate.
• Pregnancy and lactation: assess risk‑benefit, as safety data are limited.
• Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Nebivolol can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): may increase nebivolol plasma levels.
• Non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): can cause excessive bradycardia.
• Other beta‑blockers: additive negative chronotropic effects.

Moderate Interactions (Monitor Closely)

• Antihypertensive agents (e.g., ACE inhibitors, diuretics): may enhance blood pressure lowering.
• Antidiabetic drugs: nebivolol may mask hypoglycaemia symptoms.
• NSAIDs: may reduce antihypertensive efficacy.